ScottMSchuetzeMDPhD

Oncology • Ann Arbor, MI

Hematologic Oncology, Sarcoma

Professor, Internal Medicine, University of Michigan Medical School

Join to view full profile

Dr. Schuetze is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Schuetze's full profile

Already have an account?

Office
1500 East Medical Center Dr
C342 Med Inn SPC 5848
Ann Arbor, MI 48109
Phone+1 734-936-0453
Is this information wrong?

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1996 - 1999
Duke University HospitalResidency, Internal Medicine, 1993 - 1996
Oregon Health and Science University School of MedicineClass of 1993

Certifications & Licensure

MI State Medical License 2004 - 2026
NC State Medical License 1993 - 1999
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor Start of enrollment: 2003 Dec 01
Completed
Phase 2
Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans Start of enrollment: 2004 May 01
Completed
Phase 2
Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma Start of enrollment: 2004 Aug 01
Completed
Phase 2
Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans Start of enrollment: 2006 May 01
Completed
Phase 2
Trial of Dasatinib in Advanced Sarcomas Start of enrollment: 2007 May 01
Completed
Phase 2
A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma Start of enrollment: 2008 Aug 01
Completed
Phase 2
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma Start of enrollment: 2011 Nov 03
Completed
Phase 2
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma Start of enrollment: 2012 Sep 27
Completed
Phase 2
Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies Start of enrollment: 2013 Oct 01
Completed
Phase 1
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Start of enrollment: 2014 Jan 01
Completed
Phase 3
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2015 Sep 14
Active, not recruiting
Phase 3
Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma Start of enrollment: 2016 Dec 06
Completed
Phase 2
Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery Start of enrollment: 2017 Jun 20
Completed
Phase 2
Localized Leiomyosarcoma Biomarker Protocol Start of enrollment: 2023 Apr 26
Recruiting
Roles: Contact, Principal Investigator
Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas Start of enrollment: 2023 Aug 31
Recruiting
Phase 2
Roles: Contact
Metastatic Leiomyosarcoma Biomarker Protocol Start of enrollment: 2022 Dec 22
Recruiting
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Exploring Adolescent and Young Adult Cancer Survivors' Experience with Cancer Treatment-Related Symptoms: A Qualitative Analysis of Semi-Structured Interviews.
Robert Knoerl, Katherine Grandinetti, Liat Smener, Emily Doll, N Lynn Henry, Emily Walling, Anao Zhang, Debra Barton, Leslie A Fecher, Yasmin Karimi, Kristen Pettit, S...> ;Journal of Adolescent and Young Adult Oncology. 2024 Apr 18
Disparate Outcomes, Biologic and Therapeutic Differences in Pediatric versus Adult Patients with Ewing Sarcoma.
Eric Schwartz, John D Rice, Lili Zhao, Victoria Wytiaz, Rama Jasty, Scott Schuetze, Rashmi Chugh> ;Oncology. 2024 Jan 1
Outcome of Patients With Malignant Peripheral Nerve Sheath Tumors Enrolled on Sarcoma Alliance for Research Through Collaboration (SARC) Phase II Trials.
Srivandana Akshintala, Yao Lu, Karla V Ballman, Scott M Schuetze, Rashmi Chugh, Robert G Maki, Denise K Reinke, Brigitte C Widemann, AeRang Kim, Mallory, N.> ;The Oncologist. 2023 May 8
6 citations
OER-073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma.
Julio Alvarenga Thiebaud, Vinod Ravi, Samuel Litwin, Scott M Schuetze, Sujana Movva, Mark Agulnik, Andrew S Kraft, Eric D Tetzlaff, Neeta Somaiah, Margaret von Mehren> ;Cancer. 2022 Oct 1
14 citations
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.
Mrinal M Gounder, Albiruni Abdul Razak, Neeta Somaiah, Sant Chawla, Javier Martin-Broto, Giovanni Grignani, Scott M Schuetze, Bruno Vincenzi, Andrew J Wagner, Bartosz ...> ;Journal of Clinical Oncology. 2022 Aug 1
8 citations
Giant Cell Tumor of Bone: Effect of Longer Dosing Intervals of Denosumab on Tumor Control and Bone-related Complications.
Cindy Y Jiang, Lili Zhao, Scott M Schuetze, Rashmi Chugh> ;The Oncologist. 2022 Jul 5
31 citations
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade ...
Sylvia Adams, Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze, Mary D. Chamberlin, Barbara J Haley, Anna Maria Storniolo, Mridula P ...> ;Clinical Cancer Research. 2021 Oct 29
6 citations
Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.
Robin L. Jones, Thomas J. Herzog, Shreyaskumar Patel, Margaret von Mehren, Scott M. Schuetze, Brian A. Van Tine, Robert L. Coleman, Roland Elmar Knoblauch, Spyros Tria...> ;Cancer Medicine. 2021 May 7
2 citations
Trabectedin: useful in leiomyosarcoma and liposarcoma, but less so in other soft tissue sarcomas.
Scott M. Schuetze> ;Annals of Oncology. 2021 May 6
10 citations
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.
Mrinal M. Gounder, Albiruni Ryan Abdul Razak, Adrienne M Gilligan, Hoyee Leong, Xiwen Ma, Neeta Somaiah, Sant P. Chawla, Javier Martin-Broto, Giovanni Grignani, Scott ...> ;Future Oncology. 2021 Apr 15
78 citations
Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.
Erin F. Cobain, Yi-Mi Wu, Pankaj Vats, Rashmi Chugh, Francis P. Worden, David Smith, Scott M. Schuetze, Mark M. Zalupski, Vaibhav Sahai, Ajjai Alva, Anne F. Schott, Me...> ;JAMA Oncology. 2021 Apr 1
12 citations
A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma.
Neeta Somaiah, Brian A. Van Tine, Amy E. Wahlquist, Mohammed M. Milhem, Elizabeth G. Hill, Elizabeth Garrett-Mayer, Kent Armeson, Scott M. Schuetze, Christian F. Meyer...> ;Cancer. 2021 Mar 15
25 citations
Unmet medical needs and future perspectives for leiomyosarcoma patients—A position paper from the national leiomyosarcoma foundation (NLMSF) and sarcoma patients euron...
Bernd Kasper, Annie Achee, Kathrin Schuster, Roger Wilson, Gerard van Oortmerssen, Rebecca A. Gladdy, Matthew L. Hemming, Paul H. Huang, Matthew Ingham, Robin L. Jones...> ;Cancers. 2021 Feb 2
162 citations
Soft Tissue Sarcoma, Version 1.2021: Featured updates to the NCCN guidelines
Margaret von Mehren, John M. Kane, Marilyn M. Bui, Edwin Choy, Mary Connelly, Sarah M. Dry, Kristen N. Ganjoo, Suzanne George, Ricardo J. Gonzalez, Martin J. Heslin, J...> ;Journal of the National Comprehensive Cancer Network. 2020 Dec 2
16 citations
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung.
Kristin Baird, John Glod, Seth M. Steinberg, Denise K. Reinke, Joseph G. Pressey, Leo Mascarenhas, Noah Federman, Neyssa Marina, Sant P. Chawla, Joanne Lagmay, John M....> ;Sarcoma. 2020 Apr 30
26 citations
Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study.
Margaret von Mehren, Suzanne George, Michael Heinrich, Scott M. Schuetze, Jeffrey T. Yap, Jian Q. Yu, Amanda Abbott, Samuel Litwin, John Crowley, Martin G. Belinsky, K...> ;Clinical Cancer Research. 2020 Apr 15
92 citations
Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab
Emily Z. Keung, Melissa Amber Burgess, Ruth Salazar, Edwin R. Parra, Jaime Rodrigues-Canales, Vanessa Bolejack, Brian A. Van Tine, Scott M. Schuetze, Steven Attia, Ric...> ;Clinical Cancer Research. 2020 Mar 15
4 citations
Differential Outcomes and Biologic Markers of Radiation-Associated vs. Sporadic Osteosarcoma: A Single-Institution Experience.
Brittany Siontis, Jonathan B. McHugh, Emily Roberts, Lily Zhao, Dafydd G. Thomas, Dawn Owen, Laurence H. Baker, J. Sybil Biermann, Scott M. Schuetze, Rashmi Chugh> ;Frontiers in Oncology. 2020 Jan 22
22 citations
Systemic treatments in MDM2 positive intimal sarcoma : A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network
Anna Maria Frezza, Tarek Assi, Salvatore Lo Vullo, Eytan Ben-Ami, Armelle Dufresne, Kan Yonemori, Emi Noguchi, Brittany Siontis, Richard Ferraro, Paweł Teterycz, Flore...> ;Cancer. 2020 Jan 1
108 citations
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
Sant P. Chawla, Jean-Yves Blay, Piotr Rutkowski, Axel Le Cesne, Peter Reichardt, Hans Gelderblom, Robert J. Grimer, Edwin Choy, Keith M. Skubitz, Leanne L. Seeger, Sco...> ;The Lancet. Oncology. 2019 Dec 1
Correction to: Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model
Rashmi Chugh, Kent A. Griffith, Elizabeth J. Davis, Dafydd G. Thomas, J. D. Zavala, Gino Metko, Bruce Brockstein, Samir D. Undevia, Walter M. Stadler, Scott M. Schuetze> ;Annals of Oncology. 2019 Aug 1
22 citations
Primary Cardiac Sarcoma: A Rare, Aggressive Malignancy with a High Propensity for Brain Metastases.
Brittany L. Siontis, Lili Zhao, Monika Leja, Jonathan B. McHugh, Maryann Shango, Laurence H. Baker, Scott M. Schuetze, Rashmi Chugh> ;Sarcoma. 2019 Mar 10
46 citations
EWSR1-NFATC2 Translocation-Associated Sarcoma Clinicopathologic Findings in a Rare Aggressive Primary Bone or Soft Tissue Tumor
Grace Y. Wang, Dafydd G. Thomas, Jessica L. Davis, Tony Ng, Rajiv M. Patel, Paul W. Harms, Bryan L. Betz, Scott M. Schuetze, Jonathan B. McHugh, Andrew E. Horvai, Soo-...> ;The American Journal of Surgical Pathology. 2019 Aug 1
28 citations
Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazin...
Robin L. Jones, George D. Demetri, Scott M. Schuetze, Mohammed M. Milhem, Anthony D. Elias, B.A. Van Tine, John T. Hamm, Sharon Anne McCarthy, George Wang, Trilok V. P...> ;Annals of Oncology. 2018 Sep 1
22 citations
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.
Scott M. Schuetze, Vanessa Bolejack, Dafydd G. Thomas, Margaret von Mehren, Shreyaskumar Patel, Brian L. Samuels, Edwin Choy, Gina Z. D'Amato, Arthur P. Staddon, Krist...> ;JAMA Oncology. 2018 Jun 1
Join now to see all

Journal Articles

Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors
Erin F Cobain, Francis Worden, Scott M Schuetze, Mark M Zalupski, Vaibhav Sahai, Ajjai Alva, Anne F Schott, Moshe Talpaz, JAMA Oncology
Efficacy and Tolerability of Trabectedin in Elderly Patients with Sarcoma: Subgroup Analysis from a Phase 3, Randomized Controlled Study of Trabectedin or Dacarbazine ...
A Elias, M Milhem, S Patel, S M Schuetze, M L Hensley, Annals of Oncology

Press Mentions

AHA News: Cancers of the Heart Are Rare -- and Here's WhyFebruary 25th, 2019
Liposarcoma, Rare Cancer That Took Rob Ford’s Life, Hard to Treat: OncologistMarch 22nd, 2016